Share

Inhaler approved for cystic fibrosis patients

accreditation
cough
cough

The TOBI Podhaler (tobramycin inhalation powder) has been approved by the US Food and Drug Administration to treat cystic fibrosis patients infected with Pseudomonas aeruginosa, a bacterium that can damage the lungs.

Cystic fibrosis, affecting about 30 000 people in the United States, causes production of thick, sticky mucus that builds up in the lungs. This can lead to chronic bacterial infections, the FDA said in a news release.

The TOBI Podhaler, used twice daily, was evaluated in clinical trials involving 95 adults and children six years and older with cystic fibrosis. The most common side effects included cough, coughing up blood, shortness of breath, fever, mouth and throat pain, changes in voice and headache.

The antibiotic inhaler is marketed by Novartis, based in East Hanover, N.J.

More information

Medline Plus has more about cystic fibrosis.

We live in a world where facts and fiction get blurred
Who we choose to trust can have a profound impact on our lives. Join thousands of devoted South Africans who look to News24 to bring them news they can trust every day. As we celebrate 25 years, become a News24 subscriber as we strive to keep you informed, inspired and empowered.
Join News24 today
heading
description
username
Show Comments ()
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE